---
title: "TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294685292.md"
description: "In the second quarter of 2026, the global revenue reached around $240 million, with BRIUMVI U.S. net product revenue contributing about $228 million to this total."
datetime: "2026-08-03T11:03:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294685292.md)
  - [en](https://longbridge.com/en/news/294685292.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294685292.md)
generator: "portal-rs"
---

# TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance

In the second quarter of 2026, the global revenue reached around $240 million, with BRIUMVI U.S. net product revenue contributing about $228 million to this total.

### Related Stocks

- [TGTX.US](https://longbridge.com/en/quote/TGTX.US.md)

## Related News & Research

- [TG Therapeutics CEO Michael Weiss to join Cantor Global Healthcare Conference fireside chat](https://longbridge.com/en/news/297906368.md)
- [AXQ Capital LP Takes Position in TG Therapeutics, Inc. $TGTX](https://longbridge.com/en/news/298125485.md)
- [RCS - OptiBiotix Health - H&B launches FORMI™ Product containing SlimBiome®](https://longbridge.com/en/news/297738732.md)
- [YieldMax MSTR Performance & Distribution Tg 25 ETF declares $0.1464 dividend](https://longbridge.com/en/news/298360694.md)
- [Why Oracle stock rose nearly 15% last month](https://longbridge.com/en/news/298363427.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**